These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7968018)

  • 41. Nursing care of predialysis patients receiving epoetin alfa.
    Brown JM
    ANNA J; 1991 Jun; 18(3):306-14. PubMed ID: 2064456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anemia of chronic renal failure: new treatment alternative.
    Seiler S
    CANNT J; 2000; 10(3):35-9, 43-8; quiz 40-2, 49-51. PubMed ID: 11799582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 46. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure.
    Silverberg D; Wexler D; Blum M; Schwartz D; Iaina A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1021. PubMed ID: 15031380
    [No Abstract]   [Full Text] [Related]  

  • 50. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.
    Cotter D; Thamer M; Zhang Y
    Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526
    [No Abstract]   [Full Text] [Related]  

  • 51. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Case study of the anemic patient: epoetin alfa--focus on iron management.
    Kirlin LF
    ANNA J; 1995 Apr; 22(2):192-5. PubMed ID: 7786067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 54. Successful use of sodium ferric gluconate in sucrose in a patient with multiple drug allergies.
    Robbins KC; Orfitelli C
    Nephrol Nurs J; 2000 Oct; 27(5):521-3. PubMed ID: 16649328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epoetin alfa: clinical trial therapy.
    ANNA J; 1989 Aug; 16(5):344-8. PubMed ID: 2673077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
    Solak Y; Atalay H; Guney I; Turkmen K; Kaya E; Turk S
    Ren Fail; 2011; 33(3):307-11. PubMed ID: 21401355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Case management of the anemic patient. Epoetin alfa: focus on reimbursement.
    Roe WI
    ANNA J; 1992 Apr; 19(2):198-9. PubMed ID: 1586234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.
    Panesar A; Agarwal R
    Am J Kidney Dis; 2002 Nov; 40(5):924-31. PubMed ID: 12407636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case management of the anemic patient. Epoetin alfa: focus on oral iron supplementation.
    Sasak C
    ANNA J; 1991 Oct; 18(5):508-9. PubMed ID: 1953090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.